Among the genomic alterations present in cfDNA and tumor DNA (tDNA) in high-risk stage 3 and 4 breast cancer patients, TP53 and PIK3CA mutations, along with epidermal growth factor receptor (EGFR) and ERBB2 amplifications, emerged as the most common. This evidence concerns the gene ERBB2 and breast carcinoma.